Why the study?
BB therapy is a cornerstone for treating CHD, but evidence regarding the benefit of long-term BB therapy in diabetic patients with stable CHD is scarce.
Does beta-blocker therapy reduce all-cause mortality, cardiovascular mortality, and MACE in diabetic patients with stable coronary heart disease?
Does beta-blocker therapy reduce all-cause mortality, cardiovascular mortality, and MACE in diabetic patients with stable coronary heart disease?
In diabetic patients with stable coronary heart disease, beta-blocker therapy does not improve all-cause mortality and is associated with an increased risk of cardiovascular mortality and MACE.
Answers are grounded in this paper and cite their sources.
Questions routine beta-blocker use in diabetic stable CHD; hypothesis-generating and requires RCT confirmation.
BACKGROUND: β-blocker (BB) therapy is a cornerstone for the treatment of coronary heart disease (CHD). The evidence of the benefit from long-term BB therapy in diabetic patients with stable CHD is scarce. This meta-analysis summarizes the evidence relating to the BB therapy in diabetic patients with stable CHD. METHODS: . CONCLUSION: BB therapy in diabetic patients with stable CHD appears to be linked to higher mortality. Large randomized trials are needed in this population to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: